Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3371459 | 0.85 | NSD2 (0.45) | NSD2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3373222 | 0.80 | NSD2 (0.42) | NSD2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL10549973 | 0.72 | HPGD (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11967773 | 0.70 | PSEN1 (0.34) | NSD2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3372624 | 0.69 | OXTR (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22519829 | 0.68 | PSEN1 (0.32) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29438124 | 0.67 | SIGMAR1 (0.31) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16518374 | 0.67 | SIGMAR1 (0.31) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL24348262 | 0.67 | ALOX5 (0.39) | NSD2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12081534 | 0.66 | SLC6A12 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863477-B1 | 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7807709-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-10-05 | — | — | US | disclosed |
| US-20080194549-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194549-A1 | Organic Compounds | REN, ACE, OTC | NSD2 4419/4885PSEN1 822/4885PSEN2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.